Vice President, Investor Relations and Corporate Communications

Location
San Diego, California, United States
Posted
Jan 07, 2021
Ref
oIPmefwR
Hotbed
Biotech Beach
Required Education
Doctorate/PHD/MD
Position Type
Full time
Vice President, Investor Relations and Corporate Communications

Company Description
  • Pre-IPO, clinical stage biotech with lead asset in Ph 1 and potential for first-in-class mechanism
  • First precision medicine approach to GI therapeutics, with platform attracting strong partners
  • Global exclusive license to Cedars-Sinai's GI biobank and bioinformatics platform
  • Fully capitalized with top-tier investor syndicate


Prometheus is a pre-IPO biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD). The company's precision medicine platform, Prometheus 360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is a spin out of Cedars-Sinai Medical Center and partners with the hospital system for its biospecimens, clinical data, and bioinformatics.

The company is led by an exceptional management team bringing deep experience in GI and autoimmune therapies. CEO Mark McKenna joined in 2019 to refocus the organization around a precision therapeutics strategy after orchestrating a successful turnaround effort at Salix Pharmaceuticals. Mark and the executive team are guided by Prometheus' board of directors, led by Chairman Tachi Yamada, M.D., and a scientific advisory board composed of key opinion leaders in IBD, including Stephan Targan, M.D., William Sandborn, M.D. and Dermot P. McGovern, M.D., Ph.D.

The company recently secured a $130 million Series D financing with a top-tier syndicate and is attracting best-in-class collaboration partners such as Takeda and Dr. Falk. With a lead therapeutic program in Phase 1 studies and a robust emerging pipeline, the company is seeking a best-in-class immunologist to lead all of Prometheus' preclinical development efforts and be accountable for delivering a sustainable pipeline of drug candidates, from target validation through IND submission.


Description Of The Role

The Vice President, Investor Relations and Corporate Communications will be responsible for developing and executing an integrated investor relations strategy that will align to and promote the business objectives of Prometheus Biosciences, including all aspects of developing and communicating the company investment thesis to investors, analysts, media and employees.

Prometheus Biosciences is experiencing a dynamic growth period as it has filed its Investigational New Drug Application for PRA023 for both Ulcerative Colitis and Crohn's Disease. The Vice President, Investor Relations and Corporate Communications will play an integral and highly visible role in this fast-paced environment, working to shape and ensure consistency of the Company's current and future messaging. Reporting directly to the Chief Financial Officer and based at Company headquarters in San Diego, California, the Vice President, Investor Relations and Corporate Communications will partner closely with the entire management team. This executive will be expected to take a strategic, highly collaborative, and energetic approach toward the execution of the IR and communications functions and exhibit a high level of personal integrity.

Position Responsibilities


  • Develop and implement investor relations strategies and tactics with the CEO and CFO including the company's positioning and intended messaging to the financial markets.
  • Partner with the CEO and CFO to lead and manage the Company's participation on quarterly earnings calls, investment conference calls and in-house meetings, road shows, analyst days, and one-on-one meetings.
  • Lead strategic communications development, including, developing communications plan to take advantage of key Company milestones, preparing press releases, presentation decks, and earnings releases, creating management Q&As, conference call scripts, and business descriptions/other information for securities filings, the annual report and the Company website.
  • Develop relationships and maintain regular communication with individual investors and select buy-side and sell-side contacts to provide up to date information about events and market trends affecting the Company, with the goal of communicating our long-term vision.
  • Track the models utilized by analysts to value/evaluate the company's performance (i.e., trends, earnings per share, return on equity, etc.) and communicate this information to Senior Management
  • Develop a strategic proactive plan for targeted marketing activities to new and existing shareholders and potential sell-side research analysts.
  • Provide ongoing analysis and monitoring of competitor and peer group companies, institutional investors and analyst activity.
  • Cultivate shareholder and new prospects by establishing and maintaining a target list of shareholders comprising desirable holders, as well as institutions for which an existing position could grow.
  • Introduce the company to new prospects through calling plan and specific communication methods.
  • Partner with senior management to understand travel schedules and set up meetings with new prospects and management when appropriate, and ensure meeting follow up.
  • Proactively maintain and enhance the company's investor website with an eye toward institutional investor preferences.


Position Requirements


  • MBA degree in finance or a related field with 10+ years of experience .demonstrating increasing responsibility and accomplishment in investor relations in the biotech or pharmaceutical industry.
  • Formal studies in science, engineering or another technical subject preferred.
  • Proven track record of developing a positive, long-term relationship with the investment community
  • Comfortable with valuation and modeling techniques used by investors and analysts
  • Demonstrated ability to understand financial data and articulate that data and a strong understanding of finance, capital markets and securities regulations
  • Excellent communication and presentation skills, both written and verbal, with the ability to write SEC documents including 10Ks and the ability to translate and simplify complex information and explain the science
  • Ability to cultivate, influence and maintain positive relationships with internal and external stakeholders and external investors and analysts
  • Ability to work cross functionally at all levels of the organization
  • Solution oriented, flexible thinker, driver of success, with integrity
  • Strong reputation with Wall Street analysts and institutional investors
  • Ability to communicate in an in-depth fashion about scientific and clinical developments


All qualified applicants are considered for employment without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability, veteran status or other protected class.